{"DataElement":{"publicId":"4287269","version":"1","preferredName":"Prior Therapy Type Name","preferredDefinition":"Name of the type of prior therapy.","longName":"4287266v1.0:4287254v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"4287266","version":"1","preferredName":"Prior Therapy Type","preferredDefinition":"Type of prior therapy.","longName":"2747595v1.0:2223243v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2747595","version":"1","preferredName":"Prior Therapy","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.","longName":"C16124","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C96D31E-7E98-213E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-06","endDate":null,"createdBy":"UMLLOADER_CAAERS","dateCreated":"2008-05-06","modifiedBy":"ONEDATA","dateModified":"2008-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AF15C-3F10-6E57-E040-BB89AD4377D7","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4287254","version":"1","preferredName":"Prior Therapy Type Name","preferredDefinition":"Name of a previous therapy.","longName":"4287254v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Investigational drug","valueDescription":"Investigational New Drug","ValueMeaning":{"publicId":"2959607","version":"1","preferredName":"Investigational New Drug","longName":"2959607","preferredDefinition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigational New Drug","conceptCode":"C49135","definition":"A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB5264-5E08-80D2-E040-BB89AD4379BB","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB7F227B-9A40-C6F4-E040-BB89AD4335B2","beginDate":"2014-06-10","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-06-10","modifiedBy":"ONEDATA","dateModified":"2014-06-10","deletedIndicator":"No"},{"value":"Other targeted therapy","valueDescription":"Other Targeted Therapy","ValueMeaning":{"publicId":"4287255","version":"1","preferredName":"Other Targeted Therapy","longName":"4287255","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-E00F-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AF15C-3F95-6E57-E040-BB89AD4377D7","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Tumor embolization therapy","valueDescription":"Neoplasm Embolization Therapy","ValueMeaning":{"publicId":"4287256","version":"1","preferredName":"Neoplasm Embolization Therapy","longName":"4287256","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Embolization Therapy","conceptCode":"C15230","definition":"A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-E035-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E04E-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Biologic therapy","valueDescription":"Biological Therapy","ValueMeaning":{"publicId":"3198847","version":"1","preferredName":"Biological Therapy","longName":"3198847","preferredDefinition":"Biological therapy is a form of treatment that implies the administration of substances which produce a biological reaction in the organism enhancing or restoring the host immune response, modifying the behavior of cancer cells, blocking the pathways of cell neoplastic transformation and tumor ability to metastasize, or facilitating the repairment of cells damaged by aggressive forms of cancer treatment.  It includes the use of sera, antitoxins, vaccines, genes, cells, tissues, and organs","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biological Therapy","conceptCode":"C15187","definition":"A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D999C94-A599-E80A-E040-BB89AD4330DB","latestVersionIndicator":"Yes","beginDate":"2011-03-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E062-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Endocrine Therapy","valueDescription":"Endocrine Therapy","ValueMeaning":{"publicId":"3021569","version":"1","preferredName":"Endocrine Therapy","longName":"3021569","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"818DED3A-497D-17D3-E040-BB89AD4304FC","latestVersionIndicator":"Yes","beginDate":"2010-03-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E06D-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Crizotinib","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E077-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E081-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E08B-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Mitomycin-C","valueDescription":"Mitomycin C","ValueMeaning":{"publicId":"3202964","version":"1","preferredName":"Mitomycin C","longName":"3202964","preferredDefinition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E727F7D-AEE0-154D-E040-BB89AD4315DA","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E09F-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Nitrosureas","valueDescription":"Nitrosureas","ValueMeaning":{"publicId":"4287257","version":"1","preferredName":"Nitrosureas","longName":"4287257","preferredDefinition":"Nitrosureas","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-E0A9-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E0C2-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"2570169","version":"1","preferredName":"Chemotherapy","longName":"2570169","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DF26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F85AD886-E0CC-9BA3-E040-BB89AD43772C","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4287253","version":"1","preferredName":"Prior Therapy Type Name","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.:Something distinguishable as an identifiable class based on common qualities.:The words or language units by which a thing is known.","longName":"C16124:C25284:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-DFE6-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"ONEDATA","dateModified":"2014-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AD886-DFF7-9BA3-E040-BB89AD43772C","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"KEARNSD","dateModified":"2015-07-07","changeDescription":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Drug name","type":"Preferred Question Text","description":"Drug name","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AF15C-3F28-6E57-E040-BB89AD4377D7","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"KEARNSD","dateModified":"2015-07-07","changeDescription":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}